Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

T. S. Larsen*, O. W. Bjerrum, N. Pallisgaard, M. T. Andersen, M. B. Møller, H. C. Hasselbalch

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with pegylated interferon alpha-2a (Peg-IFN-2a) have been demonstrated, although follow-up was relatively short. We report here the first profound and sustained molecular responses with a JAK2 V617F allele burden below 1.0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response.

    OriginalsprogEngelsk
    Sider (fra-til)847-850
    Antal sider4
    TidsskriftAnnals of Hematology
    Vol/bind87
    Udgave nummer10
    DOI
    StatusUdgivet - 16 maj 2008

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera' indeholder.

    Citationsformater